Fabian Gonell

Fabian Gonell is Senior Vice President, Licensing Strategy and Legal Counsel of Qualcomm’s Technology Licensing division, where his responsibilities include developing the Company’s licensing strategy, negotiating license agreements, and overseeing the company’s compliance with the rules of standards organizations. He has played a major role in structuring and negotiating license agreements with many of Qualcomm’s licensees, including Apple, Samsung, LGE, Ericsson, and Nokia/Microsoft, as well as in Qualcomm’s response to regulatory investigations of Qualcomm’s licensing practices.

Prior to joining Qualcomm, Mr. Gonell was a litigator at Cravath, Swaine & Moore LLP in New York, where he represented Qualcomm and other clients in patent and antitrust litigation. He also served as an adjunct professor at the Fordham University School of Law, where he taught courses in interviewing, counseling and negotiation. Mr. Gonell holds a BA in Economics from the City University of New York and a JD from the Fordham University School of Law, where he was Editor-in-Chief of the Fordham Law Review.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More